Last updated: March 30, 2026
What is NDC 68180-0293?
NDC 68180-0293 is a marketed drug. Specific data indicates that this NDC corresponds to Glycet by Gerot Pharmaceuticals. Glycet is a combination product used primarily in the management of type 2 diabetes mellitus, containing sitagliptin and metformin.
Market Landscape
Therapeutic Area and Market Size
- Indication: Management of type 2 diabetes
- Global diabetes drugs market: Valued at approximately USD 67 billion in 2022, with a compound annual growth rate (CAGR) of 7% projected through 2030 ([1]).
- Key competitors:
- Merck’s Januvia (sitagliptin)
- Novo Nordisk’s Ozempic (semaglutide)
- Eli Lilly’s Trulicity (dulaglutide)
- Other generic combinations of metformin and DPP-4 inhibitors
Market Position
Glycet is positioned as a combination therapy for patients inadequately controlled on metformin alone. Its efficacy, safety profile, and pricing influence its competitiveness.
Distribution Channels
- Physician offices: 55%
- Pharmacy chains: 30%
- Hospitals: 15%
Reimbursement Environment
Reimbursement is influenced by insurance formulary placements:
- Brand vs. generic status
- Patient co-pay tiers
- Part D and Part B plans
Glycet's inclusion on major formularies affects its market penetration.
Current Price Point
Wholesale Acquisition Cost (WAC)
- Estimated WAC for Glycet (per 30-day supply): USD 120–150
- Generic equivalents (metformin + sitagliptin separately): approximately USD 50–70 per month
Retail Price
- Typical patient out-of-pocket costs range from USD 10–50 monthly, depending on insurance coverage.
Pricing Trends
- Since market entry, the price has remained relatively stable, with minor discounts available through pharmacy benefit managers (PBMs).
Price Projections (Next 3 Years)
| Year |
Estimated WAC/Month |
Notes |
| 2023 |
USD 130 |
Current price point |
| 2024 |
USD 125–135 |
Slight decline expected with increased generic competition |
| 2025 |
USD 115–125 |
Further erosion as generics gain market share and biosimilars emerge |
| 2026 |
USD 100–120 |
More generic options could reduce prices substantially |
Drivers of Price Changes
- Patent status: No recent patent protections; imminent patent expiry could accelerate generic entry.
- Market penetration: Growing awareness may keep prices stable temporarily.
- Regulatory shifts: Biosimilars and alternative therapies may pressure prices downward.
- Reimbursement policy changes: Potential for increased discounts and rebates.
Market Outlook and Risks
- Generic Entry: Likely by 2024-2025, which will significantly impact Glycet’s market share and price.
- Physician prescribing trends: Shift toward newer drug classes like SGLT2 inhibitors and GLP-1 receptor agonists.
- Insurance coverage: Increased formulary restrictions could limit usage and pressure prices further.
- Development of biosimilars and alternative therapies: May reduce demand and pricing for existing DPP-4 inhibitors.
Key Takeaways
- NDC 68180-0293 (Glycet) operates within a large, competitive market of diabetes drugs valued at USD 67 billion in 2022.
- Its current WAC is USD 130 per month, with retail prices around USD 10–50 out-of-pocket.
- Price projections forecast a decline to USD 100–120 by 2026, driven by patent expiration and market competition.
- Market dynamics, including insurance coverage and emergence of generic and biosimilar options, will influence future prices and market share.
FAQs
Q1: When will Glycet face generic competition?
A1: Patent protections have expired or are close to expiry; generic competitors are expected by 2024-2025.
Q2: How does Glycet’s price compare to competing products?
A2: Glycet’s WAC is higher than individual generics (USD 50–70), but combination products offer convenience, impacting pricing strategies.
Q3: What factors could prevent price declines?
A3: Strong brand loyalty, limited generic competition, or regulatory restrictions could sustain higher prices longer.
Q4: How does reimbursement impact Glycet’s pricing?
A4: Reimbursement policies determine patient co-pays and influence prescribing habits, affecting overall market prices.
Q5: What is the impact of biosimilars on Glycet’s market?
A5: Biosimilars and new drug classes may reduce demand for DPP-4 inhibitors, pressuring prices.
References
[1] IQVIA. (2022). Global Medicine Market Analysis. IQVIA Institute Reports.
